The reform of the essential medicines system in China: a comprehensive approach to universal coverage
- PMID: 23826503
- PMCID: PMC3700034
- DOI: 10.7189/jogh.03.010303
The reform of the essential medicines system in China: a comprehensive approach to universal coverage
Figures





Similar articles
-
Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji.BMC Health Serv Res. 2018 Mar 27;18(1):218. doi: 10.1186/s12913-018-2993-1. BMC Health Serv Res. 2018. PMID: 29587742 Free PMC article.
-
[Using the concept of universal health coverage to promote the health system reform in China].Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Nov 6;50(11):932-935. doi: 10.3760/cma.j.issn.0253-9624.2016.11.002. Zhonghua Yu Fang Yi Xue Za Zhi. 2016. PMID: 27903352 Chinese.
-
Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.CMAJ. 2017 Feb 27;189(8):E295-E302. doi: 10.1503/cmaj.161082. CMAJ. 2017. PMID: 28246223 Free PMC article.
-
Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective.Risk Manag Healthc Policy. 2019 Dec 18;12:357-367. doi: 10.2147/RMHP.S226379. eCollection 2019. Risk Manag Healthc Policy. 2019. PMID: 31908552 Free PMC article. Review.
-
Early appraisal of China's huge and complex health-care reforms.Lancet. 2012 Mar 3;379(9818):833-42. doi: 10.1016/S0140-6736(11)61880-1. Lancet. 2012. PMID: 22386036 Review.
Cited by
-
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.Pharmacoeconomics. 2015 Sep;33(9):905-24. doi: 10.1007/s40273-015-0293-8. Pharmacoeconomics. 2015. PMID: 26048353 Review.
-
Towards universal health coverage: lessons from 10 years of healthcare reform in China.BMJ Glob Health. 2020 Mar 19;5(3):e002086. doi: 10.1136/bmjgh-2019-002086. eCollection 2020. BMJ Glob Health. 2020. PMID: 32257400 Free PMC article. Review.
-
The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.BMC Public Health. 2020 Apr 29;20(1):588. doi: 10.1186/s12889-020-08746-x. BMC Public Health. 2020. PMID: 32349722 Free PMC article.
-
Health care utilization and affordability among older people following China's 2009 health reform -- evidence from CHARLS pilot study.Int J Equity Health. 2019 May 3;18(1):62. doi: 10.1186/s12939-019-0969-3. Int J Equity Health. 2019. PMID: 31053074 Free PMC article.
-
Temporal trends and variation in out-of-pocket expenditures and patient cost sharing: evidence from a Chinese national survey 2011-2015.Int J Equity Health. 2021 Jun 19;20(1):143. doi: 10.1186/s12939-021-01480-9. Int J Equity Health. 2021. PMID: 34147106 Free PMC article.
References
-
- OECD. Value for money in health spending. Paris: OECD Health Division, 2010.
-
- OECD. Pharmaceutical pricing policies in a global market OECD Health Policy Studies, Directorate for Employment, Labour and Social Affairs. Paris: OECD Health Division, 2008.
-
- Gustafsson LL, Wettermark B, Godman B, Andersén–Karlsson E, Bergman U, Hasselström J, et al. The ‘wise list’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108:224–33. doi: 10.1111/j.1742-7843.2011.00682.x. - DOI - PubMed
-
- Communist Party of China Central Committee. State Council. Opinions of the communist party of china central committee and the state council on deepening the health care system reform. Beijing: Government of the People's Republic of China, 2009.
-
- Communist Party of China Central Committee. State Council. Implementation plan for the recent priorities of the health care system reform (2009–2001). Beijing: Government of the People's Republic of China, 2009.
LinkOut - more resources
Full Text Sources
Other Literature Sources